The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
Adherence challenges with pre-exposure prophylaxis (PrEP) could be overcome if experimental long-acting HIV drug is found to be effective and acceptable.
Treatment access gains are to be applauded – but we will get nowhere if we don’t prevent more new infections and reach out to key affected populations.
Drug policy based on prohibition hasn't worked. It's time to build on the success of partial-decriminalisation models with an emphasis on health and human rights, says new report.
People who inject drugs are increasingly left behind in the HIV response, with limited access to harm reduction services that secure their rights and their health.
Negotiating the political minefield of global drug policy has left civil society and many progressive-thinking countries disappointed by the outcomes of last week’s United Nations General Assembly Special Session (UNGASS) on the World Drug Problem, and frustrated by the UNGASS process.
Resistance to the commonly prescribed antiretroviral drug tenofovir is ‘surprisingly common’, according to findings published in the Lancet Infectious Diseases last week.
